Company intelligence / Profile preview

Lantern Bioworks

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Lantern Bioworks has commercialized a one-time application genetically modified oral probiotic ("Lumina", BCS3-L1), designed to outcompete Streptococcus mutans and prevent dental caries; the product has not completed formal human clinical trials and is marketed via medical tourism in Prospera and pre-orders online as a cosmetic/probiotic, not a drug[5][3][6]. There are limited reports of use in ~60 people, but no published clinical efficacy or comprehensive safety data[5].

Therapeutic areas: Infectious Diseases
Modalities: ProbioticGenetically engineered microbeLive biotherapeutic product therapy
Industry: Biotech

Partnerships

Oragenics (material transfer and commercialization agreement)[4][7]

Beyond the preview

Go deeper on Lantern Bioworks.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lantern Bioworks.

Explore the full profile